James Asfour
Family Medicine · East Syracuse, NYNPI 1437786621
Payments from drug & device makers
Across 86 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$267
- Amgen$173
- AbbVie$157
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Novo Nordisk$108
- Bayer$92
- plus $543 from 18 others
What the payments were for
- Food & beverage$1,474100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $267 |
| Amgen | 12 | $173 |
| AbbVie | 12 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $133 |
| Novo Nordisk | 5 | $108 |
| Bayer | 5 | $92 |
| Exact Sciences | 5 | $87 |
| Sumitomo Pharma America, Inc. | 1 | $78 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Biogen | 2 | $35 |
| Eisai Inc. | 1 | $35 |
| AstraZeneca | 2 | $31 |
| Lilly USA, LLC | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Corium, LLC | 2 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Vertex | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$1,474 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $10,502 |
| OzempicSemaglutide | 11 | $10,018 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,093 |
| Ventolin HfaAlbuterol Sulfate | 12 | $624 |
| SynthroidLevothyroxine Sodium | 13 | $428 |
| Prazosin Hcl | 13 | $345 |
| Metoprolol Succinate | 11 | $211 |
| Atorvastatin Calcium | 40 | $198 |
| Fluticasone Propionate | 11 | $197 |
| Omeprazole | 22 | $158 |
| Metformin Hcl ErMetformin Hcl | 19 | $135 |
| Famotidine | 25 | $125 |
| Lisinopril | 37 | $124 |
| Gabapentin | 17 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $14 | $15,56022 claims |
| Novo NordiskOzempic | $108 | $10,01811 claims |
| AbbVieSynthroid | $157 | $42813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.
Other family medicine in East Syracuse
- Louis BonavitaEast Syracuse$674K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.